Anaptysbio, Inc. · NASDAQ:ANAB
Anaptysbio — Technical Presentation (March 2024)
4 slides from Anaptysbio's technical presentation, March 2024
Slide 1: ANB032, an Investigational BTLA Checkpoint Agonist Antibody, Attenuates Dendritic Cell Maturation and Function
066 ANB032, an Investigational BTLA Checkpoint Agonist Antibody, Attenuates Dendritic Cell (DC) Maturation and Function: A Novel Mechanism Addressing Atopic Dermatitis (AD) Pathophysiology Pejman Soroosh, Eric Hare, Stephen Parmley, Paul Lizzul, Martin Dahl AnaptysBio, Inc. San Diego, CA, USA Disclo
Slide 2: BTLA is a Key Node of Immune Regulation and Target for ANB032
BTLA is a Key Node of Immune Regulation and Target for ANB032 B and T Lymphocyte Attenuator (BTLA): Potent modulator of T cells, B cells, and dendritic cells Proposed Mechanism of Action for ANB032 ANB032: IgG4 antibody (non-depleting) • Binds to BTLA on membrane proximal epitope • Fc receptor bindi
Slide 3: ANB032 Reduced DC Maturation, Antigen Presentation, and Co-stimulatory Molecule Expression In Vitro
ANB032 Reduced DC Maturation, Antigen Presentation, and Co-stimulatory Molecule Expression In Vitro Muench, et al. Presented at the American Academy of Dermatology Meeting, San Diego, March 8-12, 2024. 3
Slide 4: ANB032-treated DCs Induced Functional Tregs and Reduced Inflammatory Cytokines in a MLR Assay
ANB032-treated DCs Induced Functional Tregs and Reduced Inflammatory Cytokines in a MLR Assay Conclusion • ANB032 reduced the maturation of DCs, reduced MHC II, reduced co-stimulatory molecule expression and contributed to the induction of Tregs in vitro • ANB032 is being evaluated in an ongoing Pha